This thesis considers the impact of the Finnish reference pricing system (RPS) on pharmaceutical wholesale prices. The policy, introduced in 2009, sets a maximum amount for the public reimbursement of pharmaceuticals assigned to the system. The reform was designed to improve the generic substitution practice that began in 2003. Using rich panel data for the years of 2006–2012, I apply the difference-in-differences method, exploiting the fact that some products never entered reference pricing (RP). I find statistically significant evidence that prices fell by 5.9% in 2009 and 8.7% in 2010, after which the effect disappeared. However, concern with parallel price trends between the treatment and control groups prevents causal interpretation of...
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements fo...
This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strate...
Constantly rising expenditures for pharmaceuticals require government intervention in firms’ pricing...
The evaluation assesses the effects the reference price system is expected to have on the pharmaceut...
Finland introduced the reference pricing system to the pharmaceutical market at the beginning of Apr...
The aim of the thesis is to study how the reference price system has affected price competition in t...
The reference price system is introduced in Finland in circumstances where the generic substitution...
132 pp.This study examines the impact of the implementation of a generic reference price system on p...
Reference pricing is one of the most common regulatory tools used to promote competition between pha...
AbstractObjectivesTo analyze the medium- to long-term impact of generic substitution and the referen...
Objective: To assess the impact of the introduction of a reference price system in Finland with a th...
We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies us...
The present paper evaluates the quantitative impact of a pharmaceutical reform on pharmaceutical pr...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
We study the impact of regulation on competition between brand-names and generics and pharmaceutical...
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements fo...
This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strate...
Constantly rising expenditures for pharmaceuticals require government intervention in firms’ pricing...
The evaluation assesses the effects the reference price system is expected to have on the pharmaceut...
Finland introduced the reference pricing system to the pharmaceutical market at the beginning of Apr...
The aim of the thesis is to study how the reference price system has affected price competition in t...
The reference price system is introduced in Finland in circumstances where the generic substitution...
132 pp.This study examines the impact of the implementation of a generic reference price system on p...
Reference pricing is one of the most common regulatory tools used to promote competition between pha...
AbstractObjectivesTo analyze the medium- to long-term impact of generic substitution and the referen...
Objective: To assess the impact of the introduction of a reference price system in Finland with a th...
We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies us...
The present paper evaluates the quantitative impact of a pharmaceutical reform on pharmaceutical pr...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmac...
We study the impact of regulation on competition between brand-names and generics and pharmaceutical...
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements fo...
This paper reviews the literature on reference pricing (RP) in pharmaceutical markets. The RP strate...
Constantly rising expenditures for pharmaceuticals require government intervention in firms’ pricing...